Exhibit 125 ยท Agency press announcement
FDA Approves First Treatment for COVID-19
The median time to recovery from COVID-19 was 10 days for the Veklury group compared to 15 days for the placebo group, a statistically significant difference.
FDA approved remdesivir (Veklury) for hospitalized COVID-19 patients. The announcement reported that in ACTT-1 the median time to recovery was 10 days on remdesivir and 15 days on placebo. It did not report ACTT-1's mortality result.
- Source
- U.S. Food and Drug Administration
- Date
- 22 October 2020
- Quoted from
- FDA news release, 22 Oct 2020, paragraph on ACTT-1
- Grade
- Primary record
- Document
- https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-covid-19
- Accessed
- 2026-11-09
- Cited by
- Findings citing this exhibit